MicroRNA-129 in Human Cancers: from Tumorigenesis to Clinical Treatment

Yanping Gao(Nanjing General Hospital of Nanjing Military Command), Longbang Chen(Nanjing General Hospital of Nanjing Military Command), Siqi Han(Chinese University of Hong Kong), Bing Feng(Guangzhou University of Chinese Medicine), Rui Wang(Guangdong Academy of Medical Sciences), Xiaoyuan Chu(Nanjing General Hospital of Nanjing Military Command), Lu Lu(University of Illinois Urbana-Champaign), Yitian Chen(Nanjing General Hospital of Nanjing Military Command)
Cellular Physiology and Biochemistry
January 1, 2016
10.1159/000447913
Cited by 68

Related Papers

The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE)
|The Lancet|2017|856
Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity
|Nature Immunology|2021|422
IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases
|Nature Biotechnology|2024|258
RETRACTED ARTICLE: MiR-143-3p functions as a tumor suppressor by regulating cell proliferation, invasion and epithelial–mesenchymal transition by targeting QKI-5 in esophageal squamous cell carcinoma
|Molecular Cancer|2016|151
Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway
|Scientific Reports|2016|128